Themis Medicare Ltd., a Mumbai-based pharmaceutical company with a 50-year legacy, has announced the launch of REMITHEM, a novel opioid injectable analgesic, in the Indian market. This groundbreaking medication is aimed at improving anesthesia induction, immediate post-operative care, and monitored anesthesia care.

REMITHEM: A New Era in Opioid Analgesics

Approved first in the USA in 1996, Remifentanil, the active ingredient in REMITHEM, is widely used and accepted in major markets such as the USA, Europe, Japan, and other countries. Themis Medicare has conducted extensive Phase III trials across 13 centers in India, ensuring regulatory approval for REMIFENTANIL.

REMITHEM’s Clinical Advantages Over Traditional Analgesics

REMITHEM stands out with its quick onset and offset of action, optimizing operation time and post-operative care. Clinical studies have shown REMITHEM to be superior to the standard of care Fentanyl injection in terms of pharmacokinetics, hemodynamics, and safety. Additionally, it may synergize with other anesthetic agents, potentially reducing their required dosage.

Controlled Availability and Therapeutic Benefits of REMITHEM

REMITHEM, being an opioid analgesic, will be available exclusively in licensed hospitals. This product promises to offer anesthesiologists a unique therapeutic option during critical stages of patient care.

Themis Medicare’s Commitment to Healthcare Excellence

Dr. Sachin Patel, Managing Director & CEO of Themis Medicare, emphasized the company’s dedication to delivering world-class medicines. REMITHEM, available in 1 mg and 2 mg vials, will be promoted by a specialized field force experienced in critical care and opioid products.

About Themis Medicare Ltd.:

Themis Medicare, with a robust R&D foundation and advanced manufacturing capabilities, continues to meet unmet medical needs, with the launch of REMITHEM marking another milestone in its commitment to healthcare innovation.

  Dr. Sachin Patel, India, Remifentanil, REMITHEM, Themis Medicare